Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

Abstract The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST‐2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we pres...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Naveen Pemmaraju, Claire Harrison, Vikas Gupta, Srdan Verstovsek, Bart Scott, Stephen T. Oh, Francesca Palandri, Haifa Kathrin Al‐Ali, Marta Sobas, Mary Frances McMullin, Ruben Mesa, Sarah Buckley, Karisse Roman‐Torres, Alessandro Vannucchi, Abdulraheem Yacoub
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2022-11-01
Sarja:	eJHaem
Aiheet:	myelofibrosis myeloproliferative neoplasms pacritinib safety
Linkit:	https://doi.org/10.1002/jha2.591
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!